The Food and Drug Administration's policy of publishing complete response letters has led to significant changes in how biopharmaceutical companies communicate regulatory rejections, according to experts interviewed by BioSpace on Apr. 13.
The move is seen as an effort to increase accountability and professionalism within the sector, giving investors and analysts more direct insight into the FDA's reasons for rejecting drug applications. However, some gaps remain due to redactions in the published documents and the continued privacy of meeting minutes between companies and regulators.
TD Cowen analyst Joe Thome said via email that "portions of the CRLs can be redacted, which could lead to some amount of varying interpretation of the information provided." Since last July, the FDA has published over 200 complete response letters covering applications from 2020 through 2024. The agency maintains two repositories: one for drugs that have since been approved and another for products not yet on the market. Archived letters include both recent rejections—such as Disc Medicine’s request earlier this year—and historical cases dating back to a 2002 depression drug application.
Analysts like Ritu Baral from TD Cowen say these releases have ended their reliance on company statements about FDA decisions. "The reception from the investment community has been unanimously positive," Baral told BioSpace. "Frankly, I think it brings a level of accountability and professionalism to a sector that is far from mature...this gives communication some guardrails." She described past instances where companies misrepresented or omitted key reasons behind FDA rejections—a practice now curtailed by public access to CRLs.
Disc Medicine CEO John Quisel also welcomed the change during a February investor call: "It’s remarkable, actually, to see this level of transparency," he said. "I think it’s a new standard in the availability of these complete response letters to the public, and we’re actually proud to be part of that." Thome added that making CRLs available helps clarify regulatory paths for drugs facing less common approval processes.
Still, concerns persist about intellectual property protection when details are made public. Some firms fear disclosure could harm competitive positions or reveal proprietary strategies; others support transparency if sensitive information remains protected. Regulatory consultant Steven Grossman predicted adaptation across industry: "Knowing that CRLs will become public, companies will start writing their submissions differently...There may be a mismatch in the short term, but an equilibrium will be achieved in the mid- to long-term. Two years from now, stakeholders will have forgotten why they thought this was a big deal."
